Recombinant t-PA Thrombolysis in Ischemic Stroke (ARTIS) trial demonstrated that early addition of aspirin after intravenous thrombolysis (IVT) increased the risk of symptomatic intracranial hemorrhage (SICH), with no effect on functional outcome at 3 months. 1 This apparent lack of effect can be interpreted in 3 ways: either the trial results were falsely negative, or the hypothesized antithrombotic effect has not become manifest in the long-term end point, or the hypothesis was incorrect. Early neurological deterioration (END) after IVT is related to stroke progression and recurrence, in addition to SICH, 2,3 and has been attributed to the inability to achieve or sustain vessel patency 4 and occurred less likely while on aspirin. 5 The aim of this post hoc analysis was to explore the effect of aspirin on END.
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Methods
Methodology of ARTIS has been described before. 1 Briefly, 642 aspirin-naïve ischemic stroke patients were randomized to aspirin ≤90 minutes after IVT or IVT alone. END was defined as a ≥4 points National Institutes of Health Stroke Scale worsening ≤24 hours after IVT, categorized into SICH (END SICH ) and cerebral ischemia (END CI ). Patients with END beause of other causes were excluded. Anonymized admission computed tomographic scans were evaluated by a blinded neuroradiologist and an emergency radiologist independently for Alberta Stroke Program Early CT Score, 6 ,7 the presence of a hyperdense middle cerebral artery sign, old (lacunar) infarction, and leukoaraiosis. In case of disagreement, computed tomographic scans were reviewed until consensus was reached.
Statistical analyses were done in both the intention-to-treat and per-protocol population. Potential explanatory variables that were significantly (P≤0.20) associated with END SICH or END CI in the univariate multinomial logistic regression analyses were entered into a multivariate model with forced entry of aspirin. Effect sizes were presented in (adjusted) odds ratios (ORs). Statistical uncertainty was expressed in 95% confidence intervals (CIs).
Results
Baseline characteristics were similar between the treatment groups ( 
Discussion
This post hoc analysis shows that aspirin early after IVT in ischemic stroke is related to END SICH without evidence of a beneficial effect on END CI . These results are consistent with the only other trial that investigated aspirin concomitant with IVT, which showed that patients treated with aspirin and streptokinase had higher rates of in-hospital cerebral death with ICH compared with patients receiving streptokinase only, whereas proportions of cerebral death without a ICH were similar between the groups. 8 The hypothesis of ARTIS was based on the observation that antiplatelet therapy before IVT has a beneficial effect, 5, 9 whereas more recent studies could not confirm this association. 10 Hence, from this hypothesis-testing analysis, there is no reason to assume that aspirin early after IVT has a compensatory antithrombotic effect in the acute phase. Because only 2 small transcranial Doppler studies investigated the effect of prior antiplatelet therapy on recanalization after IVT showing conflicting results, 11, 12 more studies are needed to further unravel the effects of antiplatelet therapy in combination with IVT. Stroke October 2014
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